ReviewJournal of physiology and biochemistry2026
Potassium channels in cancer: from hallmarks to therapeutic targeting.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Potassium channels constitute important signaling nodes in the progression of human cancers. Through canonical ion conduction-dependent functions, including intracellular K⁺ homeostasis, membrane potential and associated Ca²⁺ signaling, and cell volume, they influence proliferation, cell death, phenotypic plasticity, invasion and metastasis, metabolic reprogramming, and angiogenesis. Beyond ion conduction, potassium channels may affect malignant phenotypes through non-canonical mechanisms, including conformational signaling, protein interactions, transcriptional regulation, and auxiliary-subunit functions. They also contribute to tumor microenvironment remodeling by regulating immune and stromal cells and altering antitumor immune responses. However, their biological effects vary with channel subtype, tumor type, functional state, and non-canonical protein interactions, resulting in oncogenic or tumor-suppressive activity. This heterogeneity makes it hard to infer channel function from expression levels alone and also limits the development of selective therapeutic strategies. This review integrates evidence on the canonical and non-canonical functions of potassium channels across distinct cellular contexts, explains the mechanistic basis of their opposing effects, and evaluates their therapeutic potential and the major challenges to clinical translation.
Indexed as
Identifiers
42678641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.